Morten Graugaard, Orbis Medicines CEO
January 6, 2025 06:30 AM ESTUpdated 04:02 PM
Financing

Eu­ro­pean macro­cy­cle start­up Or­bis rais­es €90M

Lei Lei Wu

News Reporter

As in­ter­est grows in the abil­i­ty to lever­age cer­tain ringed mol­e­cules as drugs, Or­bis Med­i­cines has raised €90 mil­lion in new fund­ing less than a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bris­tol My­ers prunes pipeline amid new round of cost cuts

Pfiz­er hires No­var­tis on­col­o­gy ex­ec to steer its can­cer am­bi­tions

As­traZeneca takes $753M charge on aban­doned com­ple­ment drug from Alex­ion deal

J&J, In­tra-Cel­lu­lar quick­ly sealed $14B deal as three oth­ers passed on buy­ing the neu­ro drug­mak­er

Up­dat­ed: Lil­ly posts 45% sales jump, culls four pro­grams across obe­si­ty, Alzheimer's, heart fail­ure and eczema

Bris­tol My­ers launch­es fresh round of ma­jor cost cuts in bid to get ahead of patent cliff

A service from the Financial Times